Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.

ABSTRACT: Lung cancer is the leading cause of cancer-related mortality in the United States. Patients treated with adjuvant chemotherapy have a 5-year survival rate of 25% to 70% depending on stage, whereas those with advanced disease have a median survival of approximately 8 months when treated with standard platinum-based therapy. Improvements in our understanding of cancer biology have led to the development of novel agents that more precisely affect the target of interest, allowing for a more rational approach to clinical trial design. Angiogenesis, the growth of new vessels from preexisting vessels, is a fundamental step in tumor growth and progression. Inhibition of tumor-related angiogenesis has become an attractive target for anticancer therapy. Bevacizumab, a monoclonal antibody against vas

SUBMITTER: Horn L 

PROVIDER: S-EPMC3528174 | biostudies-literature | 2009 Mar

REPOSITORIES: biostudies-literature